Event
Axxam at BioJapan 2026 | Booth B-07
Jean-Francois Rolland
Senior Vice President, Early Drug Discovery
Anzai Takayuki Advisor
BD & Sales Asia & Pacific
Where biotechnology innovation meets drug discovery
New therapeutic opportunities are emerging from a deeper understanding of biology, new technologies and increasingly sophisticated approaches to disease research.
Turning these opportunities into new medicines, however, requires more than identifying promising biology. It requires the right experimental strategy to validate targets, investigate mechanisms and translate biological insights into high-quality chemical starting points.
At BioJapan 2026, Axxam will join the international biotechnology community to discuss how integrated early drug discovery can help move innovative therapeutic concepts forward.
Visit us at Booth B-07 to meet our team and explore how Axxam can support your drug discovery program from target identification and validation to assay development, screening, hit identification and hit-to-lead.
Join Axxam’s Sponsor Seminar at BioJapan 2026
📌 Where Discovery Leads – Pioneering Science for the Next Wave of Therapeutics
📅 October 8| 🕙 16:00–17:00|📍 F202
Drug discovery continues to evolve, driven by new therapeutic opportunities, emerging technologies and increasingly complex biological questions.
At the Axxam Sponsor Seminar at BioJapan 2026, Dr. Jean-Francois Rolland will share Axxam’s perspective on the scientific approaches shaping the next wave of therapeutic discovery.
The seminar will explore how different capabilities can be connected across early discovery to investigate complex biology, generate meaningful experimental evidence and support the progression of therapeutic programs.
Speaker
Dr. Jean-Francois Rolland
Senior Vice President
Early Drug Discovery, Axxam
Chair
Dr. Takayuki Anzai
Advisor
BD & Sales Asia & Pacific, Axxam
Integrated Early Drug Discovery at Axxam
Successful drug discovery requires more than a single technology. Biological understanding, robust experimental models, screening strategies and chemical expertise need to work together to answer the specific questions of each program.
As a drug discovery CRO, Axxam supports pharmaceutical and biotechnology companies with integrated and stand-alone services across early discovery.
Our capabilities include:
- Target identification and validation, connecting biological hypotheses with experimental evidence
- Biochemical and cell-based assay development for established and emerging therapeutic targets
- High-throughput screening (HTS) and high-content screening approaches
- Hit identification and characterization to identify and investigate promising starting points
- Hit-to-lead activities combining biology and medicinal chemistry
- Advanced cellular models, including human iPSC-derived systems and 3D models
- Electrophysiology and organellar electrophysiology for ion channel research
- AI-enabled and data-driven approaches connected with experimental validation
These capabilities can be combined into integrated workflows or applied individually according to the scientific needs and stage of each project.
From Biological Questions to Drug Discovery Strategies
Every discovery program starts from a different question.
For some projects, the challenge is establishing whether a biological target can provide a meaningful therapeutic opportunity. For others, it is developing an assay that captures the relevant biology, identifying active compounds or understanding how initial hits can be progressed.
Axxam brings together expertise in molecular and cell biology, pharmacology, screening technologies, advanced cellular models and medicinal chemistry to address these questions within connected discovery workflows.
This approach allows project strategies to be adapted to the target, biological context and available evidence rather than applying the same discovery path to every program.
Meet Axxam at BioJapan 2026
Are you attending BioJapan 2026 in Yokohama?
Visit Axxam at Booth B-07 from October 7–9 to meet our team and discuss your early drug discovery program.
You can talk with us about target validation, assay development, screening strategies, complex cellular models, hit discovery or broader integrated drug discovery programs.
Frequently Asked Questions
Where can I meet Axxam at BioJapan 2026?
Axxam will be at Booth B-07 during BioJapan 2026, taking place from October 7–9, 2026, in Yokohama, Japan.
Is Axxam hosting a seminar at BioJapan 2026?
Yes. Axxam will host the Sponsor Seminar “Where Discovery Leads: Pioneering Science for the Next Wave of Therapeutics” on October 8 from 16:00 to 17:00 in Room F202.
Who is speaking at the Axxam BioJapan seminar?
The seminar will feature Dr. Jean-Francois Rolland, Senior Vice President, Early Drug Discovery at Axxam, with Dr. Takayuki Anzai, Advisor, BD & Sales Asia & Pacific, as chair.
What drug discovery services does Axxam provide?
Axxam is a Contract Research Organization supporting early drug discovery with capabilities spanning target identification and validation, assay development, high-throughput and high-content screening, hit identification, hit characterization and hit-to-lead activities. Axxam also provides advanced cellular models, electrophysiology and other specialized discovery technologies.
Can I discuss my drug discovery project with Axxam at BioJapan?
Yes. Visitors can meet the Axxam team at Booth B-07 to discuss specific scientific challenges and explore suitable approaches for early drug discovery programs.